Follistatin 344
Also known as: FS-344, FST344, Follistatin
Follistatin 344 is a naturally occurring glycoprotein that functions as a potent inhibitor of myostatin, activin, and other members of the TGF-beta superfamily. It has been extensively studied for its role in promoting skeletal muscle growth and as a gene therapy candidate for muscular dystrophy.
Key Findings at a Glance
- •Transgenic mice overexpressing follistatin show 194-327% increases in muscle mass, substantially exceeding the approximately 100% increase from myostatin knockout alone due to simultaneous activin A inhibition.
- •A Phase 1/2a clinical trial in Becker muscular dystrophy demonstrated an average 11.5% improvement in six-minute walk test at 6 months (p = 0.02) with AAV1-FS344 gene therapy.
- •In nonhuman primates, AAV1-FS344 produced durable muscle hypertrophy lasting over 15 months with no disruption to reproductive hormones or cardiac tissue.
- •The FS-344 isoform was selected for clinical development because it has approximately 10-fold lower affinity for pituitary activin compared to FS-288, minimizing reproductive hormone disruption.
Follistatin 344 Overview & Molecular Profile
Follistatin 344 (FS-344) is a 344-amino acid isoform of the follistatin protein, a critical regulator of muscle mass and reproductive physiology. The protein is expressed in nearly all tissues, with particularly high concentrations in the ovaries, skin, and liver. FS-344 is processed in vivo to the circulating FS-315 isoform by removal of the C-terminal acidic tail. Follistatin gained prominence in muscle biology research when transgenic mice overexpressing follistatin demonstrated dramatic 194-327% increases in muscle mass compared to wild-type controls. Unlike myostatin-only inhibitors, follistatin simultaneously neutralizes activin A and other TGF-beta ligands, producing greater muscle hypertrophy than myostatin blockade alone. The FS-344 isoform is preferred for therapeutic research over FS-288 due to its lower affinity for activin in the pituitary, reducing the risk of disrupting reproductive hormone signaling.
Mechanism of Action: Hormonal Signaling & Receptor Binding
Follistatin 344 exerts its muscle-promoting effects primarily through high-affinity binding and neutralization of myostatin (GDF-8) and activin A, two TGF-beta superfamily ligands that act as negative regulators of skeletal muscle mass. By sequestering these ligands in the extracellular space, follistatin prevents their binding to the activin type IIB receptor (ActRIIB), thereby blocking downstream Smad2/3 phosphorylation and transcriptional suppression of muscle growth genes. Additionally, follistatin promotes satellite cell proliferation and differentiation, increasing the pool of myogenic progenitor cells available for muscle fiber hypertrophy and hyperplasia. Research in nonhuman primates has demonstrated that AAV1-mediated delivery of FS-344 produces durable increases in muscle size and strength persisting for over 15 months, with the transgene expression remaining localized to muscle tissue without systemic hormonal disruption.
Research-Observed Effects
Muscle Hypertrophy & Strength
Follistatin 344 has been demonstrated to produce pronounced skeletal muscle hypertrophy through simultaneous inhibition of myostatin and activin A signaling via the ActRIIB receptor pathway. Transgenic mouse studies have documented muscle mass increases of 194-327% compared to wild-type controls, with effects exceeding those seen with myostatin knockout alone. In nonhuman primates, AAV1-FS344 intramuscular injection produced significant and durable increases in quadriceps muscle size and strength that persisted for over 15 months without plateau. The mechanism involves both myofiber hypertrophy (increased cross-sectional area of existing fibers) and satellite cell-mediated hyperplasia (formation of new muscle fibers). Research indicates that follistatin's dual blockade of myostatin and activin produces approximately 25-30% greater muscle mass increases compared to myostatin inhibition alone, highlighting the contribution of activin A suppression to the overall anabolic response.
Muscular Dystrophy Therapeutic Potential
A Phase 1/2a clinical trial (NCT01519349) demonstrated that AAV1-FS344 gene therapy delivered by intramuscular injection to the quadriceps of patients with Becker muscular dystrophy produced measurable improvements in ambulation and muscle pathology. In the high-dose cohort, two patients improved their six-minute walk test distances by 108 meters and 29 meters respectively, representing clinically meaningful functional gains. Histological analysis of muscle biopsies revealed reduced fibrosis (35-43% of baseline levels), normalized fiber size distribution, and evidence of muscle hypertrophy. The treatment demonstrated a favorable safety profile with no serious adverse events over the 24-month follow-up period. Pooled analysis showed an average 11.5% improvement in six-minute walk test performance at 6 months (p = 0.02), with the degree of pre-existing fibrosis correlating inversely with treatment response.
Anti-Fibrotic Effects
Research demonstrates that follistatin 344 significantly reduces pathological fibrosis in skeletal muscle tissue, particularly in the context of muscular dystrophy models. In mdx mice (a model for Duchenne muscular dystrophy), transgenic follistatin expression reduced endomysial and perimysial fibrosis while simultaneously increasing functional muscle mass. The anti-fibrotic mechanism involves suppression of activin A-mediated signaling, which normally promotes fibroblast activation and collagen deposition in damaged muscle. Clinical biopsy data from Becker muscular dystrophy patients treated with AAV1-FS344 confirmed reduced fibrotic tissue content, with quantitative histomorphometry showing fibrosis levels decreasing to 35-43% of pre-treatment values. These findings suggest that follistatin may address both the primary muscle wasting and the secondary fibrotic replacement that characterizes progressive muscular dystrophies.
Reproductive Physiology Modulation
Follistatin plays an established role in regulating reproductive function through its interaction with activin in the hypothalamic-pituitary-gonadal axis. The FS-344 isoform was specifically selected for muscle therapy research because it demonstrates approximately 10-fold lower affinity for pituitary activin compared to the FS-288 isoform, minimizing disruption to FSH secretion and reproductive hormone balance. Primate studies with AAV1-FS344 confirmed that serum estradiol, testosterone, LH, and FSH levels remained within normal physiological ranges throughout 15 months of treatment. However, the broader follistatin family remains under investigation for potential applications in reproductive medicine, including polycystic ovary syndrome and fertility regulation. The differential tissue distribution and activin-binding properties of follistatin isoforms continue to inform the development of muscle-targeted therapies with minimal off-target reproductive effects.
Metabolic Regulation
Emerging research suggests that follistatin may influence metabolic homeostasis beyond its established role in muscle biology. Studies in animal models have demonstrated that increased muscle mass resulting from follistatin overexpression is associated with improved insulin sensitivity and glucose disposal, consistent with the metabolic benefits of increased lean body mass. Follistatin has been shown to modulate brown adipose tissue thermogenesis through interactions with activin and myostatin signaling in adipocytes, potentially influencing energy expenditure and fat metabolism. Research has identified circulating follistatin as an exercise-responsive factor, with plasma levels increasing acutely following resistance exercise, suggesting a role as a myokine that communicates muscle metabolic status to other tissues. These metabolic effects position follistatin at the intersection of muscle biology and whole-body energy regulation.
Research Dosing Information
In gene therapy clinical trials, AAV1-FS344 has been delivered by direct intramuscular injection at doses of 3 x 10^11 to 6 x 10^11 vector genomes per kilogram. Recombinant follistatin protein has been studied in animal models at varying doses. Researchers should consult original trial protocols for specific experimental conditions.
Note: Dosing information is provided for research reference only and is based on published studies using research subjects. This is not a recommendation for any use.
Research Studies & References
A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy
Mendell JR, Sahenk Z, Malik V, et al. (2015). Molecular Therapy
This landmark Phase 1/2a clinical trial evaluated the safety and preliminary efficacy of AAV1-FS344 gene therapy in six patients with Becker muscular dystrophy, divided into low-dose and high-dose cohorts receiving intramuscular injections to the quadriceps. The high-dose cohort demonstrated clinically meaningful improvements, with two patients improving their six-minute walk test distances by 108 meters and 29 meters respectively over the study period. Histological analysis of post-treatment muscle biopsies revealed significant reductions in endomysial fibrosis to 35-43% of baseline levels, accompanied by normalized muscle fiber size distribution and evidence of myofiber hypertrophy. The treatment was well tolerated with no serious adverse events or immune-mediated toxicities observed during the follow-up period. Immunohistochemistry confirmed sustained transgene expression in treated muscles without evidence of cellular immune responses against the follistatin protein. This trial established the first clinical proof-of-concept for follistatin gene therapy in human muscular dystrophy.
Follistatin gene therapy improves ambulation in Becker muscular dystrophy
Al-Zaidy SA, Sahenk Z, Rodino-Klapac LR, Kaspar B, Mendell JR (2015). Journal of Neuromuscular Diseases
This comprehensive review analyzed the preclinical development and clinical outcomes of AAV1-FS344 follistatin gene therapy for Becker muscular dystrophy, providing detailed context for the therapeutic rationale and isoform selection. The authors explain that the FS-344 isoform was chosen over FS-288 due to its approximately 10-fold lower affinity for pituitary activin, reducing the theoretical risk of disrupting FSH secretion and reproductive hormone balance. Pooled analysis of the Phase 1/2a trial data demonstrated a statistically significant average 11.5% improvement in six-minute walk test performance at 6 months (p = 0.02), establishing functional ambulation as a meaningful clinical endpoint. The review documents that the degree of pre-existing muscle fibrosis at baseline was the strongest predictor of treatment response, with less fibrotic muscles showing greater functional improvement. Safety data confirmed that serum reproductive hormones, liver function tests, and hematologic parameters remained within normal ranges throughout the study period. The authors conclude that follistatin gene therapy represents a viable disease-modifying approach for Becker muscular dystrophy with potential applicability to other myostatin-responsive muscle diseases.
Follistatin gene delivery enhances muscle growth and strength in nonhuman primates
Kota J, Handy CR, Haidet AM, et al. (2009). Science Translational Medicine
This pivotal preclinical study demonstrated that AAV1-mediated delivery of follistatin 344 to cynomolgus macaque monkeys produced pronounced and durable increases in muscle size and strength that persisted for over 15 months. Intramuscular injection of AAV1-FS344 into the quadriceps resulted in significant muscle hypertrophy measurable by MRI volumetric analysis, with the CMV promoter producing greater transgene expression and larger muscle size gains compared to the MCK muscle-specific promoter. Comprehensive safety evaluation revealed no abnormal changes in morphology or function of key organs including heart, liver, kidneys, and reproductive tissues. Critically, serum estradiol, testosterone, luteinizing hormone, and follicle-stimulating hormone remained at baseline levels throughout the 15-month observation period, confirming the FS-344 isoform's favorable safety profile regarding reproductive hormone regulation. No evidence of cardiac hypertrophy or systemic immune responses against the follistatin transgene was observed. These primate data provided the essential safety and efficacy foundation that justified subsequent human clinical trials in Becker muscular dystrophy.
Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease
Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR (2009). Muscle & Nerve
This comprehensive review examined the rationale and evidence supporting follistatin-based inhibition of myostatin as a therapeutic strategy for muscle-wasting diseases including muscular dystrophies, sarcopenia, and cachexia. The authors detail how transgenic mice overexpressing follistatin demonstrate muscle mass increases of 194-327% compared to wild-type animals, substantially exceeding the approximately 100% increase seen with myostatin gene knockout alone. This enhanced response is attributed to follistatin's ability to simultaneously neutralize both myostatin and activin A, two TGF-beta ligands that independently suppress muscle growth through the ActRIIB receptor. The review discusses the critical importance of isoform selection, explaining that FS-344 (processed to FS-315) targets muscle tissue while minimizing effects on pituitary function, unlike FS-288 which has high affinity for heparan sulfate proteoglycans on cell surfaces throughout the body. Preclinical data from mdx dystrophic mice demonstrate that follistatin treatment increases muscle mass, reduces pathological fibrosis and inflammation, and improves functional muscle strength. The authors conclude that follistatin gene therapy represents a mutation-independent approach applicable across diverse muscle diseases regardless of their underlying genetic cause.
Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin
Gilson H, Schakman O, Kalista S, Lause P, Tsuchida K, Thissen JP (2009). American Journal of Physiology-Endocrinology and Metabolism
This mechanistic study elucidated the cellular pathways through which follistatin promotes skeletal muscle hypertrophy, demonstrating that the effect involves both myofiber hypertrophy and satellite cell-mediated hyperplasia. Using electroporation-mediated follistatin overexpression in mouse tibialis anterior muscles, researchers showed a 30% increase in muscle mass within two weeks, accompanied by a significant increase in myofiber cross-sectional area. BrdU incorporation experiments revealed enhanced satellite cell proliferation in follistatin-treated muscles, indicating activation of the muscle stem cell compartment as a key component of the hypertrophic response. The study demonstrated that follistatin inhibited both myostatin and activin A signaling through the ActRIIB-Smad2/3 pathway, and that dual inhibition was required for the full magnitude of the hypertrophic effect. Quantitative analysis showed that follistatin-mediated muscle growth exceeded that achievable by myostatin inhibition alone by approximately 25-30%, directly attributable to the additional suppression of activin A signaling. These findings established the dual-ligand inhibition model that subsequently informed the design of clinical follistatin gene therapy programs.
Frequently Asked Questions
TB-500
C212H350N56O78S
TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4, which plays a crucial role in tissue repair, cell migration, and blood vessel formation in the body.
GHK-Cu
C14H23CuN6O4
GHK-Cu is a naturally occurring copper complex of the tripeptide glycyl-L-histidyl-L-lysine. It has been extensively studied for wound healing, skin rejuvenation, and tissue remodeling.
IGF-1 LR3
C400H625N111O115S9
IGF-1 LR3 is a modified form of insulin-like growth factor-1 with an arginine substitution at position 3 and a 13-amino acid N-terminal extension, designed to have reduced binding to IGF-binding proteins and an extended biological half-life.